Parkinson's disease
Conditions
Interventions
Parkinson's disease group:Photobiomodulation
Sponsors
The Second Affiliated Hospital of Hainan Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. At the time of signing the informed consent, age between 18 and 90 years old, no gender restrictions; 2. Diagnosis meets the MDT clinical diagnostic criteria for Parkinson's disease, with no absolute exclusion criteria; 3. H&Y stage 1-3 (early stage); 4. Stable use of anti-PD medication for more than 1 month; 5. The patient fully understands the purpose and requirements of this trial, voluntarily participates in the clinical trial and signs the written informed consent, and is willing to complete the entire trial process as required.
Exclusion criteria
Exclusion criteria: 1. Severe systemic diseases, such as: heart failure, respiratory failure, liver or kidney dysfunction, immune deficiency, malignant tumors; 2. Secondary Parkinson's syndrome caused by other secondary factors (including: thyroid dysfunction, vitamin B12 and folic acid deficiency, traumatic brain injury, cerebral infarction/hemorrhage); 3. Parkinson's overlap syndromes (such as: PSA, MSA, DLB); 4. H&Y stage = stage 4 (advanced stage); 5. Comorbidities including severe heart disease, severe joint disease or orthopedic injury, peripheral neuropathy, vascular obstruction, severe musculoskeletal disorders, or vestibular dysfunction; 6. Considered by the investigator as unsuitable for participation in this trial; 7. Psychiatric episodes or suicidal ideation in the past 12 months; 8. Conditions that may affect PBM efficacy, such as structural brain disease, epilepsy, or use of potential photosensitive drugs (imipramine, St. John's wort, phenothiazines, lithium, chloroquine, hydrochlorothiazide, tetracycline).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DTI-ALPS index on cranial MRI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Motor Function (MDS-UPDRS-III);Gait (TUG);Cognitive Function (MOCA, MMSE);Quality of Life (PDQ-39);Sleep Quality (Parkinson's Disease Sleep Scale, PDSS);Biomarkers of Neurodegenerative Diseases (such as peripheral blood P-tau217, Aß42/Aß40 ratio, p-tau181, GFAP, and NfL);Eye Movements; | — |
Countries
China
Contacts
Public ContactYong You
The Second Affiliated Hospital of Hainan Medical University
Outcome results
None listed